Alzheimer's disease and type 2 diabetes: Two diseases, one common link?

References

• Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. 1997. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128 5132.
   Google Scholar
• Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, . 2001. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12:851-855.
   PubMed Web of Science ®Google Scholar
• Baskin DG, Figlewicz DP, Woods SC, Porte D, Jr., Dorsa DM. 1987. Insulin in the brain. Annu Rev Physiol 49:335–347.
   PubMed Web of Science ®Google Scholar
• Berger J, Wagner JA. 2002. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 4:163–174.
   PubMedGoogle Scholar
• Biessels GJ, Kappelle LJ. 2005. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33:1041–1044.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. 1991. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213–216.
   PubMed Web of Science ®Google Scholar
• Carlsson CM. 2010. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 20:711–722.
   PubMed Web of Science ®Google Scholar
• de la Monte SM. 2009. Insulin resistance and Alzheimer's disease. BMB Rep 42:475–481.
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Tong M. 2009. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis 17:817–825.
   Google Scholar
• de la Monte SM, Wands JR. 2005. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7:45–61.
   PubMed Web of Science ®Google Scholar
• Gammeltoft S, Fehlmann M, Van Obberghen E. 1985. Insulin receptors in the mammalian central nervous system: binding characteristics and subunit structure. Biochimie 67: 1147 1153.
   Google Scholar
• JSR-F, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, . 2009. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 1792:432 443.
   Google Scholar
• Landreth G. 2007. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 4:159–164.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Gustafson DR. 2009. Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis 16:693–704.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. 2001. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635 641.
   Google Scholar
• Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. 2008. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 5:438 447.
   Google Scholar
• Peila R, Rodriguez BL, Launer LJ. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51: 1256 1262.
   Google Scholar
• Qiu C, De Ronchi D, Fratiglioni L. 2007. The epidemiology of the dementias: an update. Curr Opin Psychiatry 20: 380 385.
   Google Scholar
• Qiu WQ, Folstein MF. 2006. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27:190–198.
   PubMed Web of Science ®Google Scholar
• Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. 2009. Microglial VEGF receptor response is an integral chemotactic component in Alzheimer's disease pathology. J Neurosci 29: 3 13.
   Google Scholar
• Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. 2011. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626 33.
   Google Scholar
• Sims-Robinson C, Kim B, Rosko A, Feldman EL. 2010. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6:551 559.
   Google Scholar
• Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, . 2005. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis 7:63 80.
   Google Scholar
• Strachan MW, Deary IJ, Ewing FM, Frier BM. 1997. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20:438 445.
   Google Scholar
• Umegaki H. 2009. Pathophysiology of cognitive dysfunction in older people with type 2 diabetes: vascular changes or neurodegeneration? Age Ageing 39:8–10.
   PubMed Web of Science ®Google Scholar
• Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. 2003. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 24:321–331
   PubMed Web of Science ®Google Scholar
• Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, . 2009. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 30:1217 1226.
   PubMedGoogle Scholar
• Verdier Y, Penke B. 2004. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr Protein Pept Sci 5:19–31.
   PubMed Web of Science ®Google Scholar
• Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, . 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950 958.
   Google Scholar
• Watson GS, Craft S. 2003. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17:27–45.
   PubMed Web of Science ®Google Scholar
• Watson GS, Craft S. 2004. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490:97–113.
   PubMed Web of Science ®Google Scholar
• Xu W, Qiu C, Winblad B, Fratiglioni L. 2007. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56:211 216.
   Google Scholar